Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Leiva

Showing results (71-80 of 80) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 80 results.
International Journal of Cardiology. Heart & Vasculature|February 2, 2019
Gender differences and management of stroke risk of nonvalvular atrial fibrillation in an upper middle-income country: Insights from the CARMEN-AF registryJ Antonio González-Hermosillo, Manuel A Baños-González, Milton E Guevara-Valdivia, et al.
Heart (British Cardiac Society)|April 1, 2016
Effect of prior clopidogrel use on outcomes in medically managed acute coronary syndrome patientsChee Tang Chin, William E Boden, Matthew T Roe, et al.
American Heart Journal|September 21, 2015
Concomitant proton-pump inhibitor use, platelet activity, and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel and managed without revascularization: insights from the Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes trialJose Carlos Nicolau, Deepak L Bhatt, Matthew T Roe, et al.
Archivos De Cardiologia De Mexico|February 18, 2017
Safety and efficacy of fimasartan in Mexican patients with grade 1-2 essential hypertensionErnesto G Cardona-Muñoz, Agustín López-Alvarado, Ignacio Conde-Carmona, et al.
Stroke|May 17, 2019
Stroke in Patients With Peripheral Artery DiseaseBrad J Kolls, Shelly Sapp, Frank W Rockhold, et al.
Gaceta Medica De Mexico|March 17, 2023
Cardiometabolic risk factors and antithrombotic treatment in a Mexican population with atrial fibrillation and heart failure with reduced ejection fractionManuel A Baños-González, Antonio González-Hermosillo, Milton E Guevara-Valdivia, et al.
The New England Journal of Medicine|May 18, 2017
Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular DiseaseA Michael Lincoff, Stephen J Nicholls, Jeffrey S Riesmeyer, et al.
Circulation|September 27, 2019
Antithrombotic Therapy in Patients With Atrial Fibrillation and Acute Coronary Syndrome Treated Medically or With Percutaneous Coronary Intervention or Undergoing Elective Percutaneous Coronary Intervention: Insights From the AUGUSTUS TrialStephan Windecker, Renato D Lopes, Tyler Massaro, et al.
The New England Journal of Medicine|August 28, 2012
Prasugrel versus clopidogrel for acute coronary syndromes without revascularizationMatthew T Roe, Paul W Armstrong, Keith A A Fox, et al.
Archivos De Cardiologia De Mexico|June 12, 2020
Excerpts from the documents of Mexican positions and recommendations in cardiovascular diseases and COVID-19Marco A Alcocer-Gamba, Pedro Gutiérrez-Fajardo, Alfredo Cabrera-Rayo, et al.
Pageof 8

Showing results (71-80 of 80) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 80 results.
International Journal of Cardiology. Heart & Vasculature|February 2, 2019
Gender differences and management of stroke risk of nonvalvular atrial fibrillation in an upper middle-income country: Insights from the CARMEN-AF registryJ Antonio González-Hermosillo, Manuel A Baños-González, Milton E Guevara-Valdivia, et al.
Heart (British Cardiac Society)|April 1, 2016
Effect of prior clopidogrel use on outcomes in medically managed acute coronary syndrome patientsChee Tang Chin, William E Boden, Matthew T Roe, et al.
American Heart Journal|September 21, 2015
Concomitant proton-pump inhibitor use, platelet activity, and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel and managed without revascularization: insights from the Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes trialJose Carlos Nicolau, Deepak L Bhatt, Matthew T Roe, et al.
Archivos De Cardiologia De Mexico|February 18, 2017
Safety and efficacy of fimasartan in Mexican patients with grade 1-2 essential hypertensionErnesto G Cardona-Muñoz, Agustín López-Alvarado, Ignacio Conde-Carmona, et al.
Stroke|May 17, 2019
Stroke in Patients With Peripheral Artery DiseaseBrad J Kolls, Shelly Sapp, Frank W Rockhold, et al.
Gaceta Medica De Mexico|March 17, 2023
Cardiometabolic risk factors and antithrombotic treatment in a Mexican population with atrial fibrillation and heart failure with reduced ejection fractionManuel A Baños-González, Antonio González-Hermosillo, Milton E Guevara-Valdivia, et al.
The New England Journal of Medicine|May 18, 2017
Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular DiseaseA Michael Lincoff, Stephen J Nicholls, Jeffrey S Riesmeyer, et al.
Circulation|September 27, 2019
Antithrombotic Therapy in Patients With Atrial Fibrillation and Acute Coronary Syndrome Treated Medically or With Percutaneous Coronary Intervention or Undergoing Elective Percutaneous Coronary Intervention: Insights From the AUGUSTUS TrialStephan Windecker, Renato D Lopes, Tyler Massaro, et al.
The New England Journal of Medicine|August 28, 2012
Prasugrel versus clopidogrel for acute coronary syndromes without revascularizationMatthew T Roe, Paul W Armstrong, Keith A A Fox, et al.
Archivos De Cardiologia De Mexico|June 12, 2020
Excerpts from the documents of Mexican positions and recommendations in cardiovascular diseases and COVID-19Marco A Alcocer-Gamba, Pedro Gutiérrez-Fajardo, Alfredo Cabrera-Rayo, et al.
Pageof 8